NCT02395601View on ClinicalTrials.gov

A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
B-Cell Lymphoma
Interventions
DRUG

CPI-1205

Small molecule inhibitor of the enzyme EZH2

Trial Locations (6)

37203

Sarah Cannon Research Institute, Nashville

43210

The Ohio State University James Cancer Hospital, Columbus

47905

Horizon Oncology Center, Lafayette

68198

University of Nebraska Medical Center, Omaha

02114

Massachusetts General Hospital, Boston

07601

John Theurer Cancer Center, Hackensack

Sponsors
All Listed Sponsors
lead

Constellation Pharmaceuticals

INDUSTRY

NCT02395601 - A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas | Biotech Hunter | Biotech Hunter